Intas puts the fizz back into ex-Sanofi plant with generic effervescents

By Flora Southey

- Last updated on GMT

GettyImages/Martin Barraud
GettyImages/Martin Barraud

Related tags Vice president

Intas Pharmaceuticals says it ‘worked hard’ over two years to bring an ex-Sanofi manufacturing facility back into production in Newcastle, UK.

Accord Healthcare – a subsidiary of India-headquartered Intas – opened the 22-acre Fawdon site last week.

The firm said it will be the first Accord facility to produce generic effervescent medicines.

Other UK sites include Harrow, Barnstaple, Haverhill and Didcot.

“Aside from developing new products here, we’re looking to use it as a major packing centre for our activity, so we’ll bring in bulk tablets and pack to export to Europe again,” ​said Accord’s executive vice president, Europe & MENA James Burt.

“We definitely see this site and somewhere we can use as a base to export into other European countries over time,” ​he added.


Accord said it worked hard to reopen the ex-Sanofi site, purchased nearly two years ago.

Sanofi announced it would close the Fawdon plant​ on 2012, in part due to the impending loss of patents for drugs manufactured at the facility.  

Anticoagulant Plavix (clopidogrel) and generic analgesic Paracetamol (acetaminophen) were made by Sanofi at the site.

Local jobs?

Accord said it will hire up to 500 staff at the Fawdon plant.

“One of the things we’re looking to do here in the northeast – and especially in Fawdon – is to bring in local talent. We know there’s a strong pool of people from the universities here who are science based,” ​said VP European strategic operations Tony Codrey.

“We’re very keen to bring those young people and bring those skills here to this organisation,” ​he added.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us